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ABSTRACT 
 
Background: Axillary lymph node dissection as routine part of breast cancer treatment 
has been questioned in relation to the balance between benefits and morbidity. The 
purpose of this study is to determine the association of tumor size, age and histological 
grade with axillary lymph node metastasis, to determine if some patients could be 
exempted from axillary dissection.  
 
Methods: The data are derived from BreastScreen NSW, the government sponsored 
population-based breast screening program. In New South Wales (NSW) Australia 
between 1995 and 2002, 7,221 patients with invasive breast carcinoma were diagnosed 
and 5,290 patients were eligible for this study. The relationship between incidence of 
positive axillary lymph nodes and three study factors (tumor size, age and histological 
grade) was investigated by univariate and multivariate analysis. Logistic regression 
models were used to predict probability of axillary metastases.  
 
Results: The incidence of axillary lymph node metastases was 28.6% (95% CI: 27.4%- 
29.8%). Univariate analysis showed that age, tumor size and histological grade were 
significant predictors of axillary lymph node metastases (p<0.0001). Multivariate 
analysis identified age, tumor size and histological grade remained as independent 
predictors (p<0.0001). From multivariate analysis, patients with T1a (≤ 5mm) and grade 
I tumors regardless of age had 5.2% (95% CI: 1.2%- 9.3%) frequency of node 
metastases. Patients 70 years or older with grade I, T1a and T1b (6-10mm) tumors had 
4.9% (95% CI: 3.2%- 7.5%) and 6.6% (95% CI: 5.3%-8.3%) predicted frequency of 
node metastases.  
 
Conclusions: Tumor size, age and histological grade are predictors of axillary lymph 
node metastases. Routine axillary lymph node dissection could be avoided in some 
patient groups with a low frequency of involved lymph nodes if the benefits are 
considered to exceed the risks. 
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INTRODUCTION 
 
Breast cancer is the leading contributor to cancer incidence and is the most common 
cause of cancer-related death among females in Australia. A total of 11,314 new cases 
and 2,521 deaths were registered for 2000.1 
 
Axillary lymph node status is an important prognostic indicator for predicting survival 
and guiding adjuvant therapy in breast cancer patients. Axillary lymph node dissection 
(ALND) is considered the standard of care in patients with invasive breast cancer2,3,4 and 
axillary dissection and histological examination is still the most accurate way for 
assessment of axillary status.  
 
An important purpose of surgical removal of axillary lymph nodes is to provide 
prognostic information and guide effect adjuvant systemic therapy. Due to increasing 
recommendations of adjuvant therapy for node-negative patients with primary tumors 
larger than 10mm, the routine axillary dissection for staging purposes may not be 
required. Clinical analysis has proved that information from ALND did not alter 
management of women > 70 years old, unless they were classified as high risk5. Sentinel 
lymph node biopsy (SLND) was introduced in 1991, and is used as an alternative to 
complete axillary lymph node dissection in all patients with breast cancer in some 
centres.  
 
As for treatment, it has been shown that although axillary dissection reduces the 
incidence of tumor recurrence in axillary lymph nodes, it does not improve survival6,7. 
Some studies have suggested routine axillary lymph node dissection can be avoided in 
patients with pure tubular carcinomas measuring ≤ 1 cm due to a low frequency of 
axillary lymph node metastases (ALNM)8,9.  
 
The complications of ALND include lymphoedema, paraesthesia, pain and weakness of 
upper extremity that reduce in the quality of life10-12. With the increase in population-
based screening, diagnosis of breast cancer at earlier stages has increased2. Most of 
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patients detected by screening have small tumor size without ALNM13,14. ALND may be 
unnecessary for some of them.  
 
The purpose of this study is to analyze the relationship between incidence of axillary 
lymph node involvement and three study factors (age, tumor size and histological grade) 
and establish a model to identify subgroups that have low risk of ALNM and could 
avoid axillary dissection. The low risk is considered as frequency less than 10% axillary 
metastases14,15.  
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MATERIALS AND METHODS 
 
Patients  
BreastScreen NSW is the government sponsored population-based breast screening 
program for women in the state of New South Wales (NSW), Australia. Women aged 
50-69 years on the electoral roll are invited and re-invited for biennial screening; women 
40-49 years, and 70 years or older are screened on request. All patients with breast 
cancer detected by the screening program in NSW from 1995 to 2002 were studied 
through a retrospective cross-sectional review. By 1995, BreastScreen NSW was 
operating in all areas in NSW, and 1995 was the earliest year breast cancer data were 
collected centrally. The latest year of available complete data was 2002.  
 
Data 
Data collection for each patient included: size of primary tumor, the number of axillary 
lymph nodes examined, the number of lymph nodes involved with tumor, histological 
grade of tumor and patient’s age. Age categories were classified as: 40-49 years (age1), 
50-59 years (age2), 60-69 years (age3) and 70 years or older (age4). Hormone receptor 
status was not reported nor collected. A frequency distribution of the tumor size data 
indicated evidence of rounding for each mm below the standard cut-offs, with a 
significantly higher frequencies on 5mm, 10mm, and so on, compared to integers 
immediately below. Thus size categories were classified as: ≤ 5mm(size1), 6-10mm 
(size2), 11-15mm (size3), 16-20mm (size4), 21-50mm (size5) and greater than 50mm 
(size6). Tumor size was also assigned a categorical T value using the TNM System of 
the American Joint Committee on Cancer16. Over the period of the study 7,221 invasive 
breast cancers were detected; 1269 patients who did not receive axillary lymph node 
dissection, or for whom the number of examined nodes was less than 5 were excluded. 
Less than 5 nodes retrieved were taken as evidence of inadequate dissection. Patients 
with items of missing data (662) were also excluded from the study, leaving 5,290 for 
analysis. 
 
  4 
Analyses 
Comparisons of the frequency of axillary lymph node involvement between groups were 
evaluated using a chi-square method for testing the null hypothesis of no association. 
Mantel-haenszel trend test was used test for linear trend and for significance for each 
variable for axillary lymph node involvement. For tumor size, an exponential model 
y=aebx was used for curvilinear trend, where y represents frequency of lymph node 
metastasis, x represents tumor size group, a is the intercept and b is the coefficient (e is 
the base of the natural log). For age and histological grade, a linear test was applied.   
 
Multiple analyses included all variables, which were also significant in the univariate 
analysis. Logistic regression was employed, and the lowest categorical groups were 
selected as references. The equation model developed from multivariate logistic 
regression was used to obtain the value of the predicted incidence of ALNM. Exact 95% 
confidence intervals were provided for the actual and estimated proportions. For the 
actual proportions of subgroups, p+ 1.96√p(1-p)/n was used, p is proportion, n is the 
number of subjects. If np<5, Geigy Scientific Tables17 was applied. All analyses were 
performed using SAS statistical software (Version 8.02).  
 
Age-specific rates and mean of tumor size were used to evaluate selection bias by 
comparing excluded subjects with eligible subjects. The Pearson Chi-Squared test was 
applied for comparison of age groups. Student’s two-sample t test was applied for 
comparison of mean tumor sizes.  
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RESULTS 
 
The 98% of cases were T1 (79.3%) or T2 (19.3%) tumors. Overall, 1512 (28.6%) were 
found to have at least one positive axillary lymph node. The mean number of examined 
nodes was 14 (standard deviation [SD]=6.64). Median tumor size was 14 mm. Table 1 
shows the distribution of variables with the proportion of subjects in each category who 
received ALND. 
 
Selection bias 
A significant difference of age structure was found between excluded group and eligible 
group. Excluded group had higher proportions of cases in older groups, for instance, 
67.4% for age ≥ 60 years and 37.4% for age ≥ 70 years, compared with 54.1% and 
20.3% in eligible group. The difference was statistically significant (p<0.0001) 
(Appendix 2). Moreover, excluded group had smaller tumor size with mean of 11.6mm 
(standard deviation [SD] = 9.21mm), compared with 16.2mm (SD = 10.42mm) for 
eligible group (p<0.0001). 
 
Univariate analysis 
The association between age and axillary lymph node involvement is statistically 
significant (p<0.0001). The age of patients was significantly higher in negative group 
(61.6 +9.3 years) than in the positive group (59.4+9.0 years). The positive rate decreased 
from 33.5% in age range of 40-49 years to 20.8% in age ≥ 70 years (Figure 1). The trend 
of node metastasis for age groups was markedly apparent (p<0.0001). 
 
There is strong relationship between tumor size and axillary lymph nodes involvement. 
From the tumor size ≤ 5mm to greater than 50mm, the proportion of axillary lymph node 
involvement gradually increased from 9.5% to 86.7%, although there was not a 
significant difference between T1a and T1b. The trend for proportion of ALNM to the 
tumor size was apparent that metastasis rate increased as tumor size increased 
(p<0.0001) (Figure 2). A significant curvilinear trend was shown for proportion of 
ALNM by tumor size with p<0.0001. 
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A strong relationship was found between histological grade and axillary lymph node 
involvement. Grade I tumors had 19.9% axillary positive rate, compared with 31.8% for 
grade II and 36.1% for grade III (Figure 3). A similar linear trend was significantly 
found from node metastasis for histological grade (P<0.0001).  
 
Multivariate analysis 
On univariate logistic regression analysis tumor size, age and histological grade were 
identified as highly significant predictors of axillary lymph node involvement 
(p<0.0001). All the three variables were included in a multivariate modeling of the data.  
In multivariate analysis, age, tumor size and histological grade remained significant 
independent predictors of axillary lymph node involvement associated with incidence of 
ALNM (Table 2). 
 
Subgroup analysis revealed that the patients with small tumor size and low grade had 
lower nodal involvement rate than those with bigger tumor size and higher grade; 
patients in lower age group had higher axillary lymph node metastasis rate than older 
(Appendix 1). Subjects with T1a and grade I tumors regardless of age had 5.2% (95% 
CI: 1.2%-9.3%) of axillary involvement (Table 3).  
 
Predicted values 
The predicted proportion of axillary nodal involvement based on three-variable equation 
from logistic model was shown in Table 4. The following equation developed for model 
was used: P=1/[1+exp(-Y)], where  
Y=Logistic(P)= -2.4112 + 0.3174 × size2 + 1.0817 × size3 + 1.5701 × size4 + 2.3333 × 
size5 + 4.1083 × size6  + 0.1275 × age2 – 0.1263 × age3 – 0.5537 × age4 + 0.3719 × 
grade II + 0.3753 × grade III (0 for reference groups: size1, age1 and grade I). 
Two subgroups were identified as low risk of axillary metastasis: subjects aged 70 years, 
with T1a and grade I had 4.9% (95% CI: 3.2%-7.5%) axillary nodal involvement; aged 
70 years with T1b and grade II had 6.6% (95% CI: 5.3%-8.3%) axillary nodal 
involvement. 
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DISCUSSION 
 
In the current study we analyzed the data from 7,221 consecutive women diagnosed as 
invasive breast cancer by screening program during the period between 1995 and 2002 
in NSW Australia. Due to the population-based native of the program and the large 
sample size, the result is likely to be representative. 
 
In terms of axillary clearance, <5 lymph nodes examined was considered inadequate 
dissection18, and these cases were excluded from analyses. The cases with missing data 
were also excluded. We analyzed data from 5290 women with invasive breast cancer as 
the eligible group. A selection bias could exist if the exclusion of cases had markedly 
different status characteristics. By comparing age-specific rates and median tumor size 
between excluded cases and eligible cases, we found there were significantly different 
age structure and mean tumor size. Based on the results, older patients and patients with 
smaller tumor size had lower axillary lymph node metastasis, so the selection bias may 
lead to the result being over-estimated. 
 
In patients with breast cancer, axillary lymph node status is a powerful predictor of 
recurrence and prognosis. ALND has been a routine component of management of 
breast cancer for a century. The benefits of ALND are that it decreases the rate of 
axillary recurrence from 18% to 1.4%6, determines prognosis, and indicates staging for 
further adjuvant therapy. 5- year survival rate is also related to the number of ALNM, 
60% for patients with 1-3 positive nodes, but 31% for those with >4 positive nodes19. 
However, the benefits should be weighed against side effects of ALND such as 
lymphedema, nerve paraesthesia, extended recovery time and economic factors20. The 
NSABP B-04 trial suggests survival is unchanged, whether or not axillary node 
dissection is performed6. Furthermore, axillary irradiation could provide the same local 
control as surgery with fewer side effects21. The results of two randomized clinical trials 
from Canada and Denmark showed that loco-regional radiation significantly reduced 
local-regional relapses and increased 10-year survival rates22,23. Another trial reported 
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that inadequate treatment of the axillar caused significantly increased axillary recurrence 
and had an adverse impact on survival rates24. 
 
Sentinel lymph node biopsy (SLNB) is an alternative to axillary lymph node clearance 
of all patients. SLNB has been widely accepted because it is less invasive and 
reasonably accurate25-27.  Axillary dissection is then only performed when the 
histopathology of the sentinel node is positive. If the result is negative, the chance that 
remaining nodes are involved is small (<0.1%)28. Therefore, axillary dissection could be 
avoided for breast cancer patients with negative sentinel nodes. Although recent SLN 
biopsy studies around the world have suggested positive results, long-term data are 
needed before the new technique changes the standard surgical practice in breast cancer 
management. Some randomized trials, such as ALMANAC trial and NSABP- 32 trial, 
are ongoing and compare SLN biopsy with ALND in relation to local control and 
survival29,30. 
 
Recently, surgeons have become more conservative and the tendency for conservation 
therapy is clear. Elimination of ALND has been accepted for patients with ductal 
carcinoma in situ and microinvasive carcinoma31-33. Chua et al suggested that clinically 
node-negative patients with either a < 5mm, lymphovascular invasion-negative tumor, or 
a < 15mm tubular or mucinous carcinoma could avoid routine ALND34. The question 
remains: are there any factors that are indicators of ALNM, so that the risk of lymph 
node status can be evaluated and patients with potential low risk of axillary lymph node 
metastasis can avoid axillary dissection?  
 
With population-based screening introduced, more breast cancers are detected at an 
early stage with small tumor and low risk of nodal metastasis. Two series reports a less 
than 10% risk of nodal involvement in women with a T1a or T1b tumor detected by 
screening14,15.  In this study based on the Breast Screening program in NSW, 79% had 
T1 tumors and 19% had T2 tumors. Subject with a tumor < 10mm had 11.7% nodal 
involvement. The existence of selection bias may overestimate the actual ALNM. Tumor 
size has been an identified predictive factor of axillary lymph node involvement as the 
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ALNM rate increases with tumor size increase34-38. In the present study, tumor size has 
shown strongest independent predictor of ALNM. Age and histological grade have also 
consistently been found to be related to ALNM in previous studies36,38-41. Other factors 
have been shown significant predictors for nodal involvement such as lymphatic or 
vascular invasion42,43, primary tumor palpability15,44,   and estrogen and progesterone 
receptors41.  
 
Recently, the level of incidence of ALNM < 5% has been defined as low risk to avoid 
ALND45. In our study, only one subgroup had less than 5% of nodal involvement; this 
group was patients > 70 years old with T1a and grade I tumors. However, the upper 95% 
confidence interval of the rate was higher than 5% and was thus not significantly lower 
than 5%. From multivariate analysis, older patients with small tumor size and low grade 
are likely to have a low risk of axillary lymph node metastasis. Our result found patients 
with T1a and grade I, regardless of age had 5.2% (95% CI: 0.2%-9.3%) of axillary 
involvement. We also identified two low risk subgroups: T1a, grade I in age ≥ 70 years 
and T1b, grade I in age ≥ 70 with predicted metastasis rate (from logistic regression) of 
less than 10%. If patients and surgeons are willing to accept 10% as very low risk of 
nodal involvement and the value to avoid axillary dissection38,44, routine ALND could be 
avoided in patients with T1a and grade I tumors, patients aged 70 years or older with 
T1a and T1b, grade I or II  tumors.  
 
In conclusion, tumor size, histological and age are predictors of axillary lymph node 
status that help to make decision if a patient have a low or high risk of nodal metastasis. 
These results could be clinically useful and help clinicians and patients to decide if 
axillary dissection can be avoided for some groups of patients. 
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Table 1 Distribution of subjects by tumor size, age and histological grade 
 
Variable Category Number of  
patients  
Proportion  
(%) 
Tumor size (mm) 0-5 (T1a)    262  5.0 
 6-10 (T1b) 1324 25.0 
 11-15 (T1c) 1584 29.9 
 16-20 (T1c) 1025 19.4 
 21-50 (T2) 1020 19.3 
 >50 (T3)     75   1.4 
Age (years) 40-49   544 10.3 
 50-59 1884 35.6 
 60-69 1790 33.8 
 ≥ 70 1072 20.3 
Histological grade I 1817 34.3 
 II 2383 45.0 
 III 1090 20.6 
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Table 2 Association between axillary lymph node involvement and tumor size, age and histological grade 
 
ALN Positive  
 
Univariate Multivariate* Variable 
n % (95%CI) Odds ratio  
(95% CI) 
p value Odds ratio 
(95% CI) 
p value 
Tumor size 
(mm) 
   
 
<0.0001  <0.0001 
T1a (0-5)   25   9.5  (6.0-13.1) 1.00+  1.00+  
T1b (6-10) 161 12.2 (10.4-14.0) 1.31 (0.84-2.05) 0.23 1.37 (0.88-2.15) 0.16 
T1c (11-15) 369 23.3 (21.2-25.4) 2.88 (1.88-4.42) <0.0001 2.95 (1.92-4.54) <0.0001 
T1c (16-20) 352 34.3 (31.4-37.2) 4.96 (3.22-7.64) <0.0001 4.81 (3.11-7.42) <0.0001 
T2 (21-50) 540 52.9 (49.8-56.0) 10.67 (6.94-16.40) <0.0001 10.31 (6.69-15.90) <0.0001 
T3 (>50)   65 86.7 (79.1-94.3) 61.62 (28.16-134.83) <0.0001 60.84 (27.68-133.74) <0.0001 
Age (years)    <0.0001  <0.0001 
40-49 182 33.5 (29.5-37.5) 1.00+  1.00+  
50-59 609 32.3 (30.2-34.4) 0.95 (0.78-1.16) 0.62 1.14 (0.91-1.42) 0.26 
60-69 498 27.8 (25.7-29.9) 0.77 (0.62-0.94) 0.01 0.88 (0.71-1.10) 0.27 
≥ 70 223 20.8 (18.4-23.2) 0.52 (0.42-0.66) <0.0001 0.58 (0.45-0.74) <0.0001 
Histological 
grade 
   <0.0001  <0.0001 
I 361 19.9 (18.1-21.7) 1.00+  1.00+  
II 758 31.8 (29.9-33.7) 1.88 (1.63-2.17) <0.0001 1.45 (1.24-1.69) <0.0001 
III 393 36.1 (33.3-39.0) 2.27 (1.92-2.69) <0.0001 1.46 (1.21-1.75) <0.0001 
 
+ Reference category 
* Size, age and histological grade 
Bold p values are less than 0.05 
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Table 3 Frequency of cases with axillary lymph node metastases for age, tumor size 
and histological grade categories and 95% CI (%) 
 
T1a ≤ 5(mm)  
Histological grade 
Age (years) I II III 
40-49 0/12(0.0) (0.0-26.5)* 3/13(23.1) (5.0-53.8)* 2/10(20.0) (2.5-55.6)* 
50-59 4/43(9.3) (2.6-22.1)* 4/3 (12.5) (3.5-29.0)* 2/14(14.3) (1.8-42.8)* 
60-69 1/39(2.6) (0.1-13.5)* 3/25(12.0) (2.6-31.22)* 2/14(14.3) (1.8-42.8)* 
≥ 70 1/21(4.8) (0.1-23.8)* 1/16(6.3)  (0.2-30.2)* 0/9(0.0) (0.0-33.6)* 
All ages 6/115(5.2) (1.2-9.3) 11/8 (12.8) (5.7-19.9) 6/47(12.8) (3.2-22.3) 
T1b 6-10(mm)  
Histological grade 
Age (years) I II III 
40-49 5/42(11.9) (2.1-21.7) 9/49(18.4) (7.5-29.2) 2/17(11.7) (1.5-36.4)* 
50-59 28/221(12.7) (8.3-17.1) 26/192(13.5) (8.7-18.4) 6/57(10.5) (2.6-18.5) 
60-69 20/235(8.5) (4.9-12.1) 26/182(14.3) (9.2-19.4) 10/54(18.5) (8.2-28.9) 
≥ 70 8/133(6.0) (2.0-10.1) 14/112(12.5) (6.4-18.6) 7/30(23.3) (8.2-38.5) 
All ages 61/631(9.7) (7.4-12.0) 75/535(14.0) (11.1-17.0) 25/158(15.8) (10.1-21.5) 
11-15(mm)  
Histological grade 
Age (years) I II III 
40-49 8/46(17.4) (6.4-28.3) 17/69(24.6) (14.5-34.8) 7/27(25.9) (9.4-42.5) 
50-59 55/238(23.1) (17.8-28.5) 84/253(33.2) (27.4-39.0) 27/91(29.7) (20.3-39.1) 
60-69 40/211(19.0) (13.7-24.2) 46/211(21.8) (16.2-27.4) 30/102(29.4) (20.6-38.3) 
≥ 70 19/136(14.0) (8.1-19.8) 31/156(19.9) (13.6-26.1) 5/44(11.4) (2.0-20.7) 
All ages 122/631(19.3) (16.3-22.4) 178/689(25.8) (22.6-29.1) 69/264(26.1) (20.8-31.4) 
  
* np<5 (n-number of case, p-proportion of ALNM), 95% confidence interval obtained using 
Geigy Scientific Tables. 
Bold values are proportion less than 10%.
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Table 4 Frequency of axillary lymph node metastases for age, tumor size and 
histological grade categories derived from logistic regression model and 95% CI 
(%) 
 
T1a ≤ 5(mm)  
Histological grade 
Age (years) I II III 
40-49 8.2(5.4-12.5) 11.5(7.6—17.0) 11.5(7.6-17.2) 
50-59 9.2(6.2-13.5) 12.9(8.8-18.5) 12.9(8.8-18.6) 
60-69 7.3(4.9-10.9) 10.3(6.9-15.0) 10.3(6.9-15.2) 
≥ 70 4.9(3.2-7.5) 7.0(4.6-10.5) 7.0(4.5-10.6) 
T1b 6-10(mm)  
Histological grade 
Age (years) I II III 
40-49 11.0(8.6-13.9) 15.2(12.1-18.8) 15.2(11.9-19.2) 
50-59 12.3(10.3-14.6) 16.9(14.3-19.8) 16.9(14.0-20.3) 
60-69 9.8(8.1-11.8) 13.6(11.4-16.2) 13.6(11.1-16.6) 
≥ 70 6.6(5.3-8.3) 9.3(7.5-11.5) 9.3(7.5-11.5) 
11-15(mm)  
Histological grade 
Age (years) I II III 
40-49 20.9(17.2-25.2) 27.7(23.4-32.6) 27.8(23.1-33.1) 
50-59 23.1(20.2-26.3) 30.3(27.1-33.8) 30.4(26.6-34.6) 
60-69 18.9(16.4-21.8) 25.3(22.3-28.5) 25.3(21.8-29.2) 
≥ 70 13.2(11.0-15.8) 18.1(15.3-21.2) 18.1(15.0-21.8) 
 
Y=Logistic(P)= -2.4112 + 0.3174 × size2 + 1.0817 × size3 + 1.5701 × size4 + 2.3333 × size5 + 
4.1083 × size6  + 0.1275 × age2 – 0.1263 × age3 – 0.5537 × age4 + 0.3719 × grade II + 0.3753 × 
grade III. 
Where P= proportion of axillary lymph node metastasis rate. 
P=1/[1+exp(-Y)] 
95% CI=1/[1+exp(-y +/- 1.96 × SE (Y)] 
Bold subgroups are upper limits of 95% confidence interval <10%.  
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Figure 1 Proportion of ALNM by age groups 
 
 
y=a+bx. P<0.0001. 
The equation is y=39.25-4.26x.  
y=proportion of frequency of axillary lymph node metastasis  
x=age group, for instance, group 1 (40-49 years) x=1.  
a=39.25 
b= - 4.26 
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Figure 2 Proportion of ALNM by tumor size 
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y=aebx. p<0.0001. 
The equation is y=5.62e0.45x.  
y=proportion of frequency of axillary lymph node metastasis 
x=tumor size group: for instance, for group 1 (tumor size≤ 5mm) x=1. 
a=5.62 
b=0.45. 
…… Trendline  
         Empirical data 
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Figure 3 Proportion of ALNM by histological grade 
 
y=a+bx. P<0.0001. 
The equation is y=13.07+8.10x.  
y=proportion of frequency of axillay lymph node metastasis 
x=histological grade, for instance, grade I x=1.  
a=13.07 
b=8.1 
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Appendix 1-- Proportion of cases with axillary lymph node metastases 
for age, tumor size and histological grade categories (%) 
 
 ≤ 5(mm) 
 Histological grade 
Age (years) I II III 
≤ 50 0/15(0.0) 4/16(25.0) 2/12(16.7) 
>50 6/100(6.0) 7/70(10.0) 6/49(12.2) 
≤ 55 3/41(7.3) 6/30(20.0) 4/28(14.3) 
>55 3/74(4.1) 5/56(8.9) 4/33(12.1) 
≤ 60 4/59(6.8) 7/49(14.3) 6/38(15.8) 
>60 2/56(3.6) 4/37(10.8) 2/23(8.7) 
≤ 65 5/80(6.3) 7/56(12.5) 7/46(15.2) 
>65 1/35(2.9) 4/30(13.3) 1/15(6.7) 
≤ 70 5/97(5.2) 10/73(13.7) 8/52(15.4) 
>70 1/18(5.6) 1/13(7.7) 0/9(0.0) 
 6-10(mm) 
 Histological grade 
Age (years) I II III 
≤ 50 7/58(12.1) 13/63(20.6) 3/22(13.6) 
>50 54/573(9.4) 62/472(13.1) 22/136(16.2) 
≤ 55 21/157(13.4) 24/155(15.5) 7/47(14.9) 
>55 40/474(8.4) 51/380(13.4) 18/111(16.2) 
≤ 60 37/291(12.7) 38/258(14.7) 9/84(10.7) 
>60 24/340(7.1) 37/277(13.4) 16/74(21.6) 
≤ 65 46/412(11.2) 50/349(14.3) 12/109(11.0) 
>65 15/219(6.8) 25/186(13.4) 13/49(26.5) 
≤ 70 54/513(10.5) 64/439(14.6) 19/133(14.3) 
>70 7/118(5.9) 11/96(11.5) 6/25(24.0) 
 11-15(mm) 
 Histological grade 
Age (years) I II III 
≤ 50 15/67(22.4) 31/92(33.7) 9/38(23.7) 
>50 107/564(19.0) 147/597(24.6) 60/226(26.5) 
≤ 55 40/176(22.7) 71/216(32.9) 25/85(29.4) 
>55 82/455(18.0) 107/473(22.6) 44/179(24.6) 
≤ 60 67/304(22.0) 105/338(31.1) 38/131(29.0) 
>60 55/327(16.8) 73/351(20.8) 31/133(23.3) 
≤ 65 89/413(21.5) 132/444(29.7) 53/182(29.1) 
>65 33/218(15.1) 46/245(18.8) 16/82(19.5) 
≤ 70 106/518(20.5) 155/561(27.6) 64/226(28.3) 
>70 16/113(14.2) 23/128(18.0) 5/38(13.2) 
 
Bold values are proportion of ALNM less than 10%. 
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Appendix 2--Age structure comparison between excluded and eligible 
group 
 
 Eligible group Excluded group    
Age (years) Number  (%) Number  (%) Χ2 Degree of  
freedom 
P 
40-49 544 (10.3) 146 (7.9) 11.12 1 0.001 
50-59 1884 (35.6) 476 (25.0) 71.98 1 <0.0001 
60-69 1790 (33.8) 572 (30.0) 9.31 1 0.002 
≥ 70 1072 (20.3) 712 (37.4) 219.51 1 <0.0001 
All age 5290 (100) 1906 (100) 229.77 3 <0.0001* 
 
Bold p values are less than 0.05 
*Overall Pearson Chi-Square test and p value with 3 degree of freedom. 
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Appendix 3--Interaction test between age and histological grade & 
good-of-fit test for final model 
 
Model -2Log L Wald χ2 P 
Base Mode (BM) 5836.84   
BM+agegp*grade 5827.50 36.91 (9DF) 0.39 
 
Wald test for the interaction between age and histological grade, p>0.05 
 
χ2 DF P с 
2.8302 7 0.9003 0.723 
 
The model fits the data well using Hosmer-Lemeshow goodness-of-fit test (χ2=2.8302, 
7DF, P=0.723). 70.7% of pairs are concordant and с =0.723. 
 
